{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:27:10Z","timestamp":1780082830171,"version":"3.54.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Activation of inflammatory processes has been identified as a major driver of pulmonary vascular remodeling that contributes to the development of precapillary pulmonary hypertension (PH). We hypothesized that circulating markers of leukocyte activation, reflecting monocytes\/macrophages (sCD163, sCD14), T-cells (sCD25) and neutrophils (myeloperoxidase [MPO], neutrophil gelatinase-associated lipocalin [NGAL]) activity, could give prognostic information in precapillary PH. Circulating markers of leucocyte activation, sCD163, sCD14, sCD25, MPO and NGAL were measured by enzyme immunoassays in plasma from patients with idiopathic PAH (IPAH; n\u2009=\u200930); patients with PAH related to associated conditions (APAH; n\u2009=\u200944) and patients with chronic thromboembolic PH (CTEPH) (n\u2009=\u200932), and compared with 23 healthy controls. Markers of leucocyte activation were elevated in precapillary PH with particularly high levels in APAH. The elevated levels of monocyte\/macrophage marker sCD163 was independently associated with poor long-term prognosis in the group as a whole, and elevated levels of sCD25 was associated with poor prognosis in APAH, while elevated levels of sCD163 and NGAL was associated with poor prognosis in IPAH and CTEPH. Our data show leucocyte activation in precapillary PH with different profiles and impact on prognosis according to etiology. The association of sCD163 with poor outcome in fully adjusted model may be of particular interest.<\/jats:p>","DOI":"10.1038\/s41598-020-75654-w","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T11:02:54Z","timestamp":1603969374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Distinct patterns of soluble leukocyte activation markers are associated with etiology and outcomes in precapillary pulmonary hypertension"],"prefix":"10.1038","volume":"10","author":[{"given":"Tove","family":"Lekva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Gullestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaspar","family":"Broch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Aukrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne K.","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"75654_CR1","doi-asserted-by":"publisher","first-page":"j5492","DOI":"10.1136\/bmj.j5492","volume":"360","author":"T Thenappan","year":"2018","unstructured":"Thenappan, T., Ormiston, M. L., Ryan, J. J. & Archer, S. L. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ 360, j5492 (2018).","journal-title":"BMJ"},{"key":"75654_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/14779072.2016.1180976","volume":"14","author":"NF Voelkel","year":"2016","unstructured":"Voelkel, N. F., Tamosiuniene, R. & Nicolls, M. R. Challenges and opportunities in treating inflammation associated with pulmonary hypertension. Exp. Rev. Cardiovasc. Ther. 14, 939\u2013951 (2016).","journal-title":"Exp. Rev. Cardiovasc. Ther."},{"key":"75654_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cyto.2017.08.015","volume":"100","author":"J Florentin","year":"2017","unstructured":"Florentin, J. & Dutta, P. Origin and production of inflammatory perivascular macrophages in pulmonary hypertension. Cytokine 100, 11\u201315 (2017).","journal-title":"Cytokine"},{"issue":"98","key":"75654_CR4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1152\/japplphysiol.00840.2004","volume":"1985","author":"KR Stenmark","year":"2005","unstructured":"Stenmark, K. R., Davie, N. J., Reeves, J. T. & Frid, M. G. Hypoxia, leukocytes, and the pulmonary circulation. J. Appl. Physiol. 1985(98), 715\u2013721 (2005).","journal-title":"J. Appl. Physiol."},{"key":"75654_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/CIRCRESAHA.113.301141","volume":"115","author":"M Rabinovitch","year":"2014","unstructured":"Rabinovitch, M., Guignabert, C., Humbert, M. & Nicolls, M. R. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ. Res. 115, 165\u2013175 (2014).","journal-title":"Circ. Res."},{"key":"75654_CR6","doi-asserted-by":"publisher","first-page":"L229","DOI":"10.1152\/ajplung.00238.2014","volume":"308","author":"SC Pugliese","year":"2015","unstructured":"Pugliese, S. C. et al. The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. Am. J. Physiol. Lung Cell Mol. Physiol. 308, L229-252 (2015).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"75654_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cyto.2013.12.013","volume":"66","author":"M Jasiewicz","year":"2014","unstructured":"Jasiewicz, M. et al. Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension. Cytokine 66, 40\u201345 (2014).","journal-title":"Cytokine"},{"key":"75654_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12931-016-0396-6","volume":"17","author":"A Anwar","year":"2016","unstructured":"Anwar, A., Ruffenach, G., Mahajan, A., Eghbali, M. & Umar, S. Novel biomarkers for pulmonary arterial hypertension. Respir. Res. 17, 88 (2016).","journal-title":"Respir. Res."},{"key":"75654_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/cyto.b.20031","volume":"63","author":"BH Davis","year":"2005","unstructured":"Davis, B. H. & Zarev, P. V. Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels. Cytom. B Clin. Cytom. 63, 16\u201322 (2005).","journal-title":"Cytom. B Clin. Cytom."},{"key":"75654_CR10","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1097\/QAD.0000000000000735","volume":"29","author":"CL Shive","year":"2015","unstructured":"Shive, C. L., Jiang, W., Anthony, D. D. & Lederman, M. M. Soluble CD14 is a nonspecific marker of monocyte activation. AIDS 29, 1263\u20131265 (2015).","journal-title":"AIDS"},{"key":"75654_CR11","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.4049\/jimmunol.135.5.3172","volume":"135","author":"LA Rubin","year":"1985","unstructured":"Rubin, L. A. et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 135, 3172\u20133177 (1985).","journal-title":"J. Immunol."},{"key":"75654_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.abb.2018.01.004","volume":"640","author":"Y Aratani","year":"2018","unstructured":"Aratani, Y. Myeloperoxidase: its role for host defense, inflammation, and neutrophil function. Arch. Biochem. Biophys. 640, 47\u201352 (2018).","journal-title":"Arch. Biochem. Biophys."},{"key":"75654_CR13","doi-asserted-by":"crossref","first-page":"10425","DOI":"10.1016\/S0021-9258(18)82217-7","volume":"268","author":"L Kjeldsen","year":"1993","unstructured":"Kjeldsen, L., Johnsen, A. H., Sengelov, H. & Borregaard, N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 268, 10425\u201310432 (1993).","journal-title":"J. Biol. Chem."},{"key":"75654_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Galie","year":"2016","unstructured":"Galie, N. et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 37, 67\u2013119 (2016).","journal-title":"Eur. Heart J."},{"key":"75654_CR15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1513\/pats.200701-018AW","volume":"4","author":"AM Pastva","year":"2007","unstructured":"Pastva, A. M., Wright, J. R. & Williams, K. L. Immunomodulatory roles of surfactant proteins A and D: implications in lung disease. Proc. Am. Thorac. Soc. 4, 252\u2013257 (2007).","journal-title":"Proc. Am. Thorac. Soc."},{"key":"75654_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00296-010-1691-z","volume":"32","author":"W Nakayama","year":"2012","unstructured":"Nakayama, W. et al. Serum levels of soluble CD163 in patients with systemic sclerosis. Rheumatol. Int. 32, 403\u2013407 (2012).","journal-title":"Rheumatol. Int."},{"key":"75654_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1600-0609.2004.00318.x","volume":"74","author":"DJ Schaer","year":"2005","unstructured":"Schaer, D. J. et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur. J. Haematol. 74, 6\u201310 (2005).","journal-title":"Eur. J. Haematol."},{"key":"75654_CR18","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/art.22416","volume":"56","author":"J Bleesing","year":"2007","unstructured":"Bleesing, J. et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 56, 965\u2013971 (2007).","journal-title":"Arthritis Rheum."},{"key":"75654_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/003655102762377466","volume":"237","author":"HJ Moller","year":"2002","unstructured":"Moller, H. J. et al. Soluble CD163: a marker molecule for monocyte\/macrophage activity in disease. Scand. J. Clin. Lab Invest. Suppl. 237, 29\u201333 (2002).","journal-title":"Scand. J. Clin. Lab Invest. Suppl."},{"key":"75654_CR20","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1164\/rccm.201202-0335OC","volume":"186","author":"R Savai","year":"2012","unstructured":"Savai, R. et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 186, 897\u2013908 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"75654_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1183\/09031936.00009914","volume":"46","author":"R Quarck","year":"2015","unstructured":"Quarck, R., Wynants, M., Verbeken, E., Meyns, B. & Delcroix, M. Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 46, 431\u2013443 (2015).","journal-title":"Eur. Respir. J."},{"key":"75654_CR22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1189\/jlb.72.4.711","volume":"72","author":"KA Hintz","year":"2002","unstructured":"Hintz, K. A. et al. Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J. Leukoc. Biol. 72, 711\u2013717 (2002).","journal-title":"J. Leukoc. Biol."},{"key":"75654_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.5603\/FHC.2011.0052","volume":"49","author":"K Kowal","year":"2011","unstructured":"Kowal, K. et al. CD163 and its role in inflammation. Folia Histochem. Cytobiol. 49, 365\u2013374 (2011).","journal-title":"Folia Histochem. Cytobiol."},{"key":"75654_CR24","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1161\/CIRCULATIONAHA.110.978627","volume":"123","author":"E Vergadi","year":"2011","unstructured":"Vergadi, E. et al. Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation 123, 1986\u20131995 (2011).","journal-title":"Circulation"},{"key":"75654_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1165\/rcmb.2015-0404LE","volume":"56","author":"B Ranchoux","year":"2017","unstructured":"Ranchoux, B. et al. Gut-lung connection in pulmonary arterial hypertension. Am. J. Respir. Cell Mol. Biol. 56, 402\u2013405 (2017).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"75654_CR26","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.chest.2016.01.004","volume":"149","author":"A Huertas","year":"2016","unstructured":"Huertas, A. et al. Regulatory T cell dysfunction in idiopathic, heritable and connective tissue-associated pulmonary arterial hypertension. Chest 149, 1482\u20131493 (2016).","journal-title":"Chest"},{"key":"75654_CR27","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000111548","volume":"75","author":"S Ulrich","year":"2008","unstructured":"Ulrich, S., Nicolls, M. R., Taraseviciene, L., Speich, R. & Voelkel, N. Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. Respiration 75, 272\u2013280 (2008).","journal-title":"Respiration"},{"key":"75654_CR28","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00380-015-0727-4","volume":"31","author":"Y Sada","year":"2016","unstructured":"Sada, Y. et al. Non-suppressive regulatory T cell subset expansion in pulmonary arterial hypertension. Heart Vessels. 31, 1319\u20131326 (2016).","journal-title":"Heart Vessels."},{"key":"75654_CR29","doi-asserted-by":"publisher","first-page":"247372","DOI":"10.1155\/2014\/247372","volume":"2014","author":"S Gaowa","year":"2014","unstructured":"Gaowa, S. et al. Effect of Th17 and Treg axis disorder on outcomes of pulmonary arterial hypertension in connective tissue diseases. Mediators Inflamm. 2014, 247372 (2014).","journal-title":"Mediators Inflamm."},{"key":"75654_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrcardio.2015.169","volume":"13","author":"X Meng","year":"2016","unstructured":"Meng, X. et al. Regulatory T cells in cardiovascular diseases. Nat. Rev. Cardiol. 13, 167\u2013179 (2016).","journal-title":"Nat. Rev. Cardiol."},{"key":"75654_CR31","doi-asserted-by":"publisher","first-page":"e47748","DOI":"10.1371\/journal.pone.0047748","volume":"7","author":"SE Russell","year":"2012","unstructured":"Russell, S. E., Moore, A. C., Fallon, P. G. & Walsh, P. T. Soluble IL-2Ralpha (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice. PLoS ONE 7, e47748 (2012).","journal-title":"PLoS ONE"},{"key":"75654_CR32","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/CIRCHEARTFAILURE.115.002225","volume":"8","author":"T Nevers","year":"2015","unstructured":"Nevers, T. et al. Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure. Circ. Heart Fail. 8, 776\u2013787 (2015).","journal-title":"Circ. Heart Fail."},{"key":"75654_CR33","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1161\/CIRCULATIONAHA.113.007101","volume":"129","author":"F Laroumanie","year":"2014","unstructured":"Laroumanie, F. et al. CD4+ T cells promote the transition from hypertrophy to heart failure during chronic pressure overload. Circulation 129, 2111\u20132124 (2014).","journal-title":"Circulation"},{"key":"75654_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3389\/fmed.2018.00217","volume":"5","author":"S Taylor","year":"2018","unstructured":"Taylor, S., Dirir, O., Zamanian, R. T., Rabinovitch, M. & Thompson, A. A. R. The role of neutrophils and neutrophil elastase in pulmonary arterial hypertension. Front. Med. (Lausanne) 5, 217 (2018).","journal-title":"Front. Med. (Lausanne)"},{"key":"75654_CR35","doi-asserted-by":"publisher","first-page":"e97530","DOI":"10.1172\/jci.insight.97530","volume":"3","author":"A Klinke","year":"2018","unstructured":"Klinke, A. et al. Myeloperoxidase aggravates pulmonary arterial hypertension by activation of vascular Rho-kinase. JCI Insight 3, e97530 (2018).","journal-title":"JCI Insight"},{"key":"75654_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000360689","volume":"37","author":"C Ronco","year":"2014","unstructured":"Ronco, C. et al. Neutrophil gelatinase-associated lipocalin: ready for routine clinical use? An international perspective. Blood Purif. 37, 271\u2013285 (2014).","journal-title":"Blood Purif."},{"key":"75654_CR37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1086\/690018","volume":"7","author":"NP Nickel","year":"2017","unstructured":"Nickel, N. P. et al. Kidney dysfunction in patients with pulmonary arterial hypertension. Pulm Circ. 7, 38\u201354 (2017).","journal-title":"Pulm Circ."},{"key":"75654_CR38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/joim.12131","volume":"275","author":"R Kaiser","year":"2014","unstructured":"Kaiser, R., Seiler, S., Held, M., Bals, R. & Wilkens, H. Prognostic impact of renal function in precapillary pulmonary hypertension. J. Intern. Med. 275, 116\u2013126 (2014).","journal-title":"J. Intern. Med."},{"key":"75654_CR39","first-page":"491","volume":"18","author":"M Yildiz","year":"2017","unstructured":"Yildiz, M., Sahin, A., Behnes, M. & Akin, I. An expanding role of biomarkers in pulmonary arterial hypertension. Curr. Pharm. Biotechnol. 18, 491\u2013494 (2017).","journal-title":"Curr. Pharm. Biotechnol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75654-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75654-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75654-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T21:45:59Z","timestamp":1696974359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75654-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["75654"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-75654-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"16 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18540"}}